Neoplasia, Journal Year: 2024, Volume and Issue: 57, P. 101049 - 101049
Published: Sept. 11, 2024
Language: Английский
Essays in Biochemistry, Journal Year: 2025, Volume and Issue: unknown
Published: May 20, 2025
Extracellular vesicles (EVs), secreted by all cellular organisms, are pivotal mediators of intercellular communication. By transporting biologically active cargos such as proteins, lipids, and nucleic acids, EVs facilitate transfer molecular signals, effectively reflecting the characteristics their parent cells. Immune cellderived (iEVs) play a crucial role in activation regulation both adaptive innate immune responses. In context activation, iEVs drive cell development well enhance antigen presentation through direct cross-dressing mechanisms. Furthermore, act signaling entities within immunological synapses, significantly amplifying response efficiency. regulation, modulate expression checkpoint (IC) molecules sustain homeostasis immunosuppressive cytokines microRNAs, thereby mitigating excessive reactions. Nevertheless, mechanistic underpinnings iEV-mediated presentation, immunoregulation remain inadequately explored. This review provides comprehensive overview functions from diverse origins underlying It also examines cutting-edge engineering strategies targeting cells, while discussing promising applications oncology immune-related diseases. These insights lay foundation for rational next-generation immunotherapies. While promising, clinical translation is hindered low yield, high batch-to-batch variability, insufficient The final section discusses key challenges potential solutions.
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: May 23, 2025
Macrophages, key players in the immune system, exhibit diverse roles tumor progression and regulation. Macrophages release extracellular vesicles (EVs), membrane-bound particles that facilitate intercellular communication cargo transfer. Macrophage-derived EVs (M-EVs) demonstrate a complex dual function development, with their effects dependent on origin microenvironment. M1-EVs show anti-tumor properties by reversing escape, while M2-EVs promote biogenesis, invasion, metastasis, therapeutic resistance. Tumor-associated macrophage-derived (TAM-EVs) generally but may characteristics specific cancers. M-EVs, particularly M1-EVs, promise as drug delivery vehicles tumor-targeted therapy due to targeting capabilities ability cross physiological barriers. Despite challenges clinical application, ongoing research aims harness potential of M-EVs for more effective personalized cancer treatments. This review summarizes how influence cell behavior, mechanisms action, related specificity, isolation, application. Collectively, this comprehensive analysis not only provides researchers better understanding biology also lights way innovative strategies, potentially advancing development
Language: Английский
Citations
0
Bioconjugate Chemistry, Journal Year: 2024, Volume and Issue: 35(7), P. 867 - 882
Published: June 26, 2024
Cancer immunotherapy has yielded remarkable results across a variety of tumor types. Nevertheless, the complex and immunosuppressive microenvironment within solid tumors poses significant challenges to established therapies such as immune checkpoint blockade (ICB) chimeric antigen receptor T-cell (CAR-T) therapy. Within milieu, tumor-associated macrophages (TAMs) play role by directly suppressing functionality fostering an environment. Effective regulation TAMs is, therefore, crucial enhancing efficacy immunotherapies. Various therapeutic strategies targeting TAM modulation have emerged, including blocking recruitment, direct elimination, promoting repolarization toward M1 phenotype, phagocytic capacity against cells. The recently introduced CAR macrophage (CAR-M) therapy opens new possibilities for macrophage-based immunotherapy. Compared with CAR-T, CAR-M may demonstrate superior infiltration capabilities tumors. This review predominantly delves into origin development process TAMs, their in growth, provides comprehensive overview immunotherapies TAMs. It underscores significance regulating bolstering antitumor while discussing potential developing targets
Language: Английский
Citations
3
Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(48)
Published: Aug. 13, 2024
Abstract METTL3 has emerged as a promising therapeutic target in cancer treatment, although its oncogenic functions melanoma development and potential for targeting drug have not been fully explored. In this study, we define the role of progression. Building on insight, examine our recently designed peptide inhibitor RM3 , which targets binding interface METTL3/14 complex disruption subsequent ubiquitin‐mediated proteasomal degradation via E3 ligase STUB1. treatment reduces proliferation, migration, invasion, induces apoptosis cells vitro vivo. Subsequent transcriptomic analysis identified changes immuno‐related genes following ‐mediated suppression N 6 ‐methyladenosine (m A) methyltransferase activity, suggesting interaction with immunotherapy. A combination anti‐PD‐1 antibody results significantly higher beneficial tumor response vivo, good safety profile. Collectively, these findings only delineate but also showcase acting degrader, novel strategy treatment.
Language: Английский
Citations
3
Neoplasia, Journal Year: 2024, Volume and Issue: 57, P. 101049 - 101049
Published: Sept. 11, 2024
Language: Английский
Citations
3